|
BR112020019065A2
|
|
STABLE AQUEOUS ANTI-TAU ANTIBODY FORMULATIONS
|
|
US2020282075A1
|
|
Albumin-modified nanoparticles carrying a targeting ligand
|
|
AU2018318692A1
|
|
Macrocyclic MCL-1 inhibitors and methods of use
|
|
BR112020003180A2
|
|
macrocyclic mcl-1 inhibitors and methods of use
|
|
WO2019016112A1
|
|
1,2,3,4-substituted quinoline compounds as s1p modulators
|
|
WO2018175449A1
|
|
Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
|
|
JP2018095656A
|
|
Tricyclic quinoline and quinoxaline derivative
|
|
EP3535244A1
|
|
Spiro-compounds as s1p modulators
|
|
US2020055817A1
|
|
Spiro-compounds as sip modulators
|
|
WO2017157929A1
|
|
Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
|
|
US2017217850A1
|
|
Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
|
|
TW201730148A
|
|
Fused (hetero)cyclic compounds as S1P modulators
|
|
EP3380483A1
|
|
Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
|
|
WO2017085693A1
|
|
Reporter gene assay methods for identifying and analyzing multi-specific binding proteins
|
|
WO2017085212A2
|
|
Surface-modified nanospheres encapsulating antigen-binding molecules
|
|
US2017050959A1
|
|
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
|
|
EP3377110A1
|
|
Nanoparticles based on optionally alkoxylated poly(alkyl cyanoacrylates) having a defined degree of polymerization
|
|
EP3353155A1
|
|
Pyridyl or pyrazinyl compounds carrying a methyl-bound alpha-amino acid amide group
|
|
CA2998183A1
|
|
Methods for treating relapsing forms of multiple sclerosis
|
|
AU2016202780A1
|
|
Powdered protein compositions and methods of making same
|
